Medical/Pharmaceuticals APAC News & Press Release Distribution

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 21:34 1736

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 21:30 1814

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that Prof.Weiming Li, ...

2024-12-10 21:27 1687

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...

2024-12-10 20:48 1600

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-12-10 08:30 1528

Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients withHuntington's Disease Volumetric MRI measurement is also approved as exploratory study endpoint BOSTON, Dec. 10, 2024 /PRNewswire/ -- Skyhawk Therapeu...

2024-12-10 00:47 1373

TraceLink Successfully Completes Industry-Leading Audits: ISO/IEC 27001:2022, ISO/IEC 27017:2015, SOC 2/ISAE 3000 Type II, and CyberVadis

Independent Audits Confirm TraceLink's Compliance with Leading Global Security Standards, Ensuring Customer Data Protection BOSTON, Dec. 9, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has reinforced its leader...

2024-12-09 23:00 1308

Seoul National University Bundang Hospital Establishes the first "International PSP Research and Treatment Center" in Korea

* MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center * Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and treatment hub for the rare neurodegenerative disease" SEOUL, South Korea, Dec. 9, 2024 /PRNe...

2024-12-09 22:00 2005

Seoul National University Bundang Hospital Establishes the first

BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL

SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- A newly published collaborative study [1] in theJournal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for managing fibrotic diseases –...

2024-12-09 12:40 1319

BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL

Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. * CS5001 is well tolerated in heavily...

2024-12-09 08:20 1544

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2024-12-09 08:00 1772

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth. This year, EpiVax expanded the b...

2024-12-07 11:30 3442

Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations

SINGAPORE, Dec. 6, 2024 /PRNewswire/ -- IMAGINE AI is the largest calendar event inSingapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potential of AI in healthcare. Hosted at the Marina Bay Sands Expo & Convention Centre, thi...

2024-12-06 10:41 7103

Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations

SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center

* SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 * Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ13731...

2024-12-06 09:00 1960

SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center

Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in theAsia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sens...

2024-12-06 08:07 1748

Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024

SYDNEY, Dec. 6, 2024 /PRNewswire/ -- Kaneka Ubiquinol™ has been awarded the covetedRaw Material Supplier of the Year Award 2024 at the Complementary Medicines Australia (CMA) Awards, held inSydney this evening.

2024-12-06 06:10 1931

KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024

AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership

HAMILTON, ON, Dec. 5, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, is pleased to announce the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer. Dr. Chattopadhyay brings over 25 years of commercial and technical ...

2024-12-05 22:00 973

AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership

Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.

* First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). * FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devicesthat could provide more effe...

2024-12-05 21:03 1562

Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.

LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System

Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings * Replaces time-consuming manual spot checking with continuous, near real-time active patient monitoring * Web-based system displays mult...

2024-12-05 20:00 1260

LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

EAST RUTHERFORD, N.J., Dec. 5, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly...

2024-12-05 19:00 1315